TABLE 2.
Vectors and plasmids used in this study
| Plasmid | Character | Vector | Reference |
|---|---|---|---|
| pGFP316 | CEN URA3 GFP | Our stock | |
| pYO326 | 2μ URA3 | Ohya et al. (1991) | |
| pJJ215 | HIS3 | Jones and Prakash (1990) | |
| pJJ242 | URA3 | Jones and Prakash (1990) | |
| pJJ250 | LEU2 | Jones and Prakash (1990) | |
| pJJ280 | TRP1 | Jones and Prakash (1990) | |
| pYM116A | 2μ TRP1 lexA-DBD | Our stock | |
| pYM116B | 2μ TRP1 lexA-DBD | Our stock | |
| pACT | 2μ LEU2 AD | This study | |
| pGAD-C1 | 2μ LEU2 AD | James et al. (1996) | |
| pTS910CU | CEN URA3 GFP | Our stock | |
| pTS910IT | TRP1 GFP | Our stock | |
| pTS911CT | CEN TRP1 PGAL1-5xHA | Our stock | |
| pGAL-GFP | 2μ PGAL1-GFP | Our stock | |
| pBluescript II KS+ | TOYOBO | ||
| pM-1 | CEN URA3 CDC3-GFP (−1000 to +1560) | pGFP316 | Iwase and Toh-e (2001) |
| pM-2 | CEN URA3 CDC10-GFP (−1000 to +968) | pGFP316 | Iwase and Toh-e (2001) |
| pM-3 | CEN URA3 CDC11-GFP (−1000 to +1244) | pGFP316 | Iwase and Toh-e (2004) |
| pM-4 | CEN URA3 CDC12-GFP (−1000 to +1223) | pGFP316 | Iwase and Toh-e (2001) |
| pM-7 | URA3 SHS1-GFP (+601 to +1655) | pJJ242 | Iwase et al. (2004) |
| pM-9 | 2μ URA3 CDC3 (−1000 to +1560) | pYO326 | This study |
| pM-10 | 2μ URA3 CDC10 (−1000 to +968) | pYO326 | This study |
| pM-11 | 2μ URA3 CDC11 (−1000 to +1244) | pYO326 | This study |
| pM-12 | 2μ URA3 CDC12 (−1000 to +1223) | pYO326 | Iwase and Toh-e (2001) |
| pM-13 | 2μ URA3 SHS1 (−1600 to +1653) | pYO326 | This study |
| pM-15 | 2μ TRP1 lexA-DBD-CDC3 (+1 to +1560) | pMY116B | Iwase and Toh-e (2001) |
| pM-16 | 2μ TRP1 lexA-DBD-CDC10 (+3 to +968) | pMY116B | Iwase and Toh-e (2001) |
| pM-17 | 2μ TRP1 lexA-DBD-CDC11 (+1 to +1244) | pMY116A | Iwase and Toh-e (2001) |
| pM-19 | 2μ TRP1 lexA-DBD-CDC12 (+1 to +1223) | pMY116B | Iwase and Toh-e (2001) |
| pM-20 | 2μ TRP1 lexA-DBD-SHS1 (+1 to +1655) | pMY116A | Iwase and Toh-e (2001) |
| pM-25 | 2μ LEU2 AD-SHS1 (+1 to +1655) | pACT | This study |
| pM-26 | 2μ LEU2 AD-SHS1 (+1 to +1655) | pGAD-C1 | This study |
| pM-30 | CDC10 (−1000 to +968) | pBluescript II KS+ | This study |
| pM-31 | cdc10Δ∷URA3 (−1000 to −141, +679 to +968) | pM-30 | This study |
| pM-32 | cdc10Δ∷LEU2 (−1000 to −141, +679 to +968) | pM-30 | This study |
| pM-33 | CDC11 (−1000 to +1244) | pBluescript II KS+ | This study |
| pM-34 | cdc11Δ∷TRP1 (−1000 to −25, +571 to +1244) | pM-33 | This study |
| pM-37 | SHS1 (−460 to +1655) | pBluescript II KS+ | This study |
| pM-38 | shs1Δ∷HIS3 (−460 to −38, +1300 to +1655) | pM-37 | This study |
| pM-91 | 2μ URA3 PGAL1 GFP-SHS1(+1 to +1655) | pGAL-GFP | This study |
| pM-92 | 2μ TRP1 PGAL1-CDC10-5xHA (+1 to +966) | pTS911CT | This study |
| pM-93 | 2μ LEU2 AD SHS1 (+1 to +271) | pGAD-C1 | This study |
| pM-94 | 2μ LEU2 AD-SHS1 (+271 to +955) | pGAD-C1 | This study |
| pM-95 | 2μ LEU2 AD-SHS1 (+1 to +760) | pGAD-C1 | This study |
| pM-96 | 2μ LEU2 AD-SHS1 (+140 to +1300) | pGAD-C1 | This study |
| pM-98 | 2μ LEU2 AD-SHS1 (+1 to +1557) | pGAD-C1 | This study |
| pM-99 | HIS3 SHS1 (+756 to +1557) | pJJ215 | This study |
| pM-101 | CEN URA3 SHS1-GFP (−1600 to +1653) | pTS910CU | This study |
| pM-102 | CEN URA3 SHS1-GFP (−1600 to +1557) | pTS910CU | This study |
| pM-108 | TRP1 MYO1-GFP (+4000 to +5784) | pTS910IT | This study |
| pM-109 | 2μ LEU2 AD-SHS1 (+1 to +1557) | pACT | This study |
| pM-2001 | 2μ LEU2 AD-SHS1 (+1 to +1062) | pACT | This study |
| r26-5 | 2μ LEU2 AD-SHS1 (+932 to +1656) | pACT | This study |
| IQG1pUG35 | CEN URA3 MET25p-IQG1-yEGFP3 | pUG35 | Wagner et al. (2002) |